Aeterna Zentaris (AEZS) 1.18 $AEZS
Stock to Watch: AEterna Zentaris Down 7.8% (AEZS)
Comtex SmarTrend(R) - Mon Oct 13, 11:41AM CDT
AEterna Zentaris (NASDAQ:AEZS) is one of today's worst performing low-priced stocks, down 7.8% to $1.18 on 1.3x average daily volume. AEterna Zentaris has traded 1.7 million shares thus far today, vs. average volume of 1.3 million shares per day. The stock has underperformed the Dow (-7.8% to the Dow's -0.3%) and underperformed the S&P 500 (-7.8% to the S&P's -0.5%) during today's trading.
AEZS: 1.18 (+0.05)
Endometrial Cancer - Pipeline Review, H2 2014
M2 - Wed Oct 08, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wds2pr/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Bristol-Myers Squibb - Sanofi - GlaxoSmithKline - Daiichi Sankyo - Merck & Co - Novartis - BioMarin Pharmaceutical - Eisai - ImmunoGen - Genmab - Exelixis - AEterna Zentaris Inc. - Ariad Pharmaceuticals, Inc. - Oncothyreon Inc. - Critical Outcome Technologies Inc. - ArQule, Inc. - Galena Biopharma, Inc. - Scancell Holdings Plc - Oryzon Genomics S.A. - Acceleron Pharma, Inc. - Arno Therapeutics, Inc. - Endocyte, Inc. - Esperance Pharmaceuticals, Inc. - Pharmsynthez - Shenogen Pharma Group Ltd. - Igenica Biotherapeutics, Inc. - Karyopharm Therapeutics, Inc. - OncoHoldings, Inc. For more information visit http://www.researchandmarkets.com/research/wd...ndometrial
BMRN: 74.71 (+3.71), ARQL: 1.15 (-0.04), BMY: 51.95 (+1.39), GSK: 43.63 (+0.02), ONTY: 1.90 (+0.17), ECYT: 5.58 (-0.03), MRK: 55.13 (+1.08), AEZS: 1.18 (+0.05), GALE: 1.92 (+0.09), NVS: 88.61 (+0.71), XLRN: 29.13 (-0.03), KPTI: 34.24 (-0.77)
Aeterna Zentaris Appoints Phil Theodore as Chief Administrative Officer, General Counsel and Corporate Secretary
PR Newswire - Tue Oct 07, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"
today announced the appointment of Philip A. Theodore, as Senior Vice President, Chief Administrative Officer, General Counsel and Corporate Secretary. Before joining Aeterna Zentaris, Mr. Theodore was Vice President, General Counsel and Corporate Secretary of Zep Inc., a leading consumable chemical packaged goods company.
AEZ.TO: 1.33 (+0.05), AEZS: 1.18 (+0.05), ZEP: 14.86 (+0.01)
Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences
PR Newswire - Tue Sep 30, 7:50AM CDT
Investor-Edge has initiated coverage on the following equities: Immunomedics Inc. (NASDAQ: IMMU), Aeterna Zentaris Inc. (NASDAQ: AEZS), OPKO Health Inc. (NYSE: OPK), Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB), and Exact Sciences Corporation (NASDAQ: EXAS). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, September 29, 2014, the NASDAQ Composite ended at 4,505.85, down 0.14%, the Dow Jones Industrial Average finished the day 0.25% lower at 17,071.22, and the S&P 500 closed at 1,977.80, down 0.25%. The losses were broad based as nine out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 744.38, down 0.18%, while the index has advanced 0.92% in the last one month. Register for your complimentary reports on these five stocks at:
IMMU: 3.65 (unch), NAVB: 1.46 (+0.04), OPK: 8.39 (+0.03), AEZS: 1.18 (+0.05), EXAS: 24.22 (+0.36)
Aeterna Zentaris to Present at Upcoming Rodman & Renshaw Annual Global Investment Conference in New York
PR Newswire - Tue Sep 02, 3:15PM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company" today announced that the Company's Chairman and CEO, David Dodd, will be presenting a corporate overview at the Rodman & Renshaw 16th Annual Global Investment Conference on Tuesday, September 9, 2014, at 3:20pm (Eastern), in the Holmes II Salon (4th floor) of the New York Palace Hotel in New York City.
AEZ.TO: 1.33 (+0.05), AEZS: 1.18 (+0.05)
Hot Stock: AEterna Zentaris, Shares Gain 5.4% (AEZS)
Comtex SmarTrend(R) - Fri Aug 29, 10:38AM CDT
AEterna Zentaris (NASDAQ:AEZS) is one of today's best performing low-priced stocks, up 5.4% to $1.48 on 3.9x average daily volume. Thus far today, AEterna Zentaris has traded 2.7 million shares, vs. average volume of 682,000 shares per day. The stock has outperformed the Dow (5.4% to the Dow's 0.0%) and outperformed the S&P 500 (5.4% to the S&P's 0.2%) during today's trading.
AEZS: 1.18 (+0.05)
Momentum Indicators for Biotech Stocks -- Exact Sciences, BioCryst Pharma, Spectrum Pharma, Aeterna Zentaris, and CTI BioPharma
PR Newswire - Mon Aug 25, 7:50AM CDT
On Friday, August 22, 2014, the NASDAQ Composite ended at 4,538.55, up 0.14%, the Dow Jones Industrial Average declined 0.22%, to finish the day at 17,001.22, and the S&P 500 closed at 1,988.40, down 0.20%. The losses were broad based as seven out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day flat at 727.35, and the index has advanced 6.75% in the previous three months. Investor-Edge has initiated coverage on the following equities: Exact Sciences Corporation (NASDAQ: EXAS), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), Aeterna Zentaris Inc. (NASDAQ: AEZS), and CTI BioPharma Corporation (NASDAQ: CTIC). Free research on these five companies can be accessed at:
BCRX: 11.37 (-0.23), AEZS: 1.18 (+0.05), SPPI: 7.62 (+0.13), EXAS: 24.22 (+0.36), CTIC: 2.37 (-0.02)
4 Stocks Under $10 to Trade Now
at The Street - Fri Aug 15, 5:00AM CDT
Stocks making big-percentage moves are usually in play because their sector is becoming attractive or they have a major fundamental catalyst.
SALT: 5.19 (+0.23), SNSS: 1.47 (-0.03), AEZS: 1.18 (+0.05), RBCN: 4.43 (+0.22)
Aeterna Zentaris Reports Second Quarter 2014 Financial and Operating Results
PR Newswire - Thu Aug 07, 3:30PM CDT
All amounts are in US dollars
AEZ.TO: 1.33 (+0.05), AEZS: 1.18 (+0.05)
Aeterna Zentaris to Present at Upcoming Canaccord Genuity 34th Annual Global Growth Conference in Boston
CNW Group - Wed Aug 06, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company" today announced that the Company's Chairman, CEO, David Dodd, will be presenting a corporate overview at the Canaccord Genuity 34th Annual Global Growth Conference on Wednesday, August 13, 2014, at 1pm (Eastern), in the Melbourne Room of the Intercontinental Hotel in Boston.
AEZ.TO: 1.33 (+0.05), AEZS: 1.18 (+0.05)
Aeterna Zentaris and ASCEND Therapeutics Sign Co-Promotion Agreement for U.S. Market
PR Newswire - Tue Aug 05, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company" today announced a strategic co-promotion services agreement with ASCEND Therapeutics® US, LLC, ("ASCEND" . Under the terms of the agreement, expected to start in the fourth quarter of 2014, Aeterna Zentaris will use its newly established commercial structure to market, in specific U.S. territories, ASCEND's EstroGel® a non-patch transdermal U.S. Food & Drug Administration ("FDA" approved and commercialized estrogen replacement therapy. For its part, ASCEND would market, in specific U.S. territories, MacrilenTM, Aeterna Zentaris' product for use in the evaluation of adult growth-hormone deficiency ("AGHD" , for which a New Drug Application ("NDA" is currently under review by the FDA, with a Prescription Drug User Fee Act ("PDUFA" date of November 5, 2014. In consideration for these co-promotion services, each party will be entitled to receive, from the other party, commissions on net sales of each other's product.
AEZ.TO: 1.33 (+0.05), AEZS: 1.18 (+0.05)
Aeterna Zentaris to Announce Second Quarter 2014 Financial and Operating Results on August 7, 2014
CNW Group - Thu Jul 31, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company" will announce its second quarter 2014 financial and operating results after market close on Thursday, August 7, 2014. The Company will host a conference call to discuss these results on Friday, August 8, 2014, at 8:30 a.m. eastern time.
AEZ.TO: 1.33 (+0.05), AEZS: 1.18 (+0.05)
Equities to Watch in the Health Care Sector -- ImmunoCellular Therapeutics, Aeterna Zentaris, Lexicon Pharma, BioDelivery Sciences Intl., and Jazz Pharma
PR Newswire - Wed Jul 23, 7:40AM CDT
On Tuesday, July 22, 2014, the NASDAQ Composite ended at 4,456.02, up 0.71%, the Dow Jones Industrial Average finished the day 0.36% higher at 17,113.54, and the S&P 500 closed at 1,983.53, up 0.50%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 713.75, up 0.83%, with the index also advancing 5.99% in the previous three months. Investor-Edge has initiated coverage on the following equities: ImmunoCellular Therapeutics Ltd (NYSE MKT: IMUC), Aeterna Zentaris Inc. (NASDAQ: AEZS), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), BioDelivery Sciences International Inc. (NASDAQ: BDSI), and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Free research on these five companies can be accessed at:
BDSI: 16.35 (-0.39), LXRX: 1.35 (+0.03), JAZZ: 159.35 (+6.96), AEZS: 1.18 (+0.05), IMUC: 0.71 (-0.01)
Traders Get Bullish on Shares of AEterna Zentaris, Shares Up 6.6% (AEZS)
Comtex SmarTrend(R) - Wed Jul 02, 10:09AM CDT
AEterna Zentaris (NASDAQ:AEZS) is one of today's best performing low-priced stocks, up 6.6% to $1.29 on 7.0x average daily volume. AEterna Zentaris has traded 2.7 million shares thus far today, vs. average volume of 386,000 shares per day. The stock has outperformed the Dow (6.6% to the Dow's 0.1%) and outperformed the S&P 500 (6.6% to the S&P's 0.1%) during today's trading.
AEZS: 1.18 (+0.05)
Stock to Watch: AEterna Zentaris Down 7.8% (AEZS)
Comtex SmarTrend(R) - Mon Oct 13, 11:41AM CDT
AEterna Zentaris (NASDAQ:AEZS) is one of today's worst performing low-priced stocks, down 7.8% to $1.18 on 1.3x average daily volume. AEterna Zentaris has traded 1.7 million shares thus far today, vs. average volume of 1.3 million shares per day. The stock has underperformed the Dow (-7.8% to the Dow's -0.3%) and underperformed the S&P 500 (-7.8% to the S&P's -0.5%) during today's trading.
AEZS: 1.18 (+0.05)
Endometrial Cancer - Pipeline Review, H2 2014
M2 - Wed Oct 08, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wds2pr/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Bristol-Myers Squibb - Sanofi - GlaxoSmithKline - Daiichi Sankyo - Merck & Co - Novartis - BioMarin Pharmaceutical - Eisai - ImmunoGen - Genmab - Exelixis - AEterna Zentaris Inc. - Ariad Pharmaceuticals, Inc. - Oncothyreon Inc. - Critical Outcome Technologies Inc. - ArQule, Inc. - Galena Biopharma, Inc. - Scancell Holdings Plc - Oryzon Genomics S.A. - Acceleron Pharma, Inc. - Arno Therapeutics, Inc. - Endocyte, Inc. - Esperance Pharmaceuticals, Inc. - Pharmsynthez - Shenogen Pharma Group Ltd. - Igenica Biotherapeutics, Inc. - Karyopharm Therapeutics, Inc. - OncoHoldings, Inc. For more information visit http://www.researchandmarkets.com/research/wd...ndometrial
BMRN: 74.71 (+3.71), ARQL: 1.15 (-0.04), BMY: 51.95 (+1.39), GSK: 43.63 (+0.02), ONTY: 1.90 (+0.17), ECYT: 5.58 (-0.03), MRK: 55.13 (+1.08), AEZS: 1.18 (+0.05), GALE: 1.92 (+0.09), NVS: 88.61 (+0.71), XLRN: 29.13 (-0.03), KPTI: 34.24 (-0.77)
Aeterna Zentaris Appoints Phil Theodore as Chief Administrative Officer, General Counsel and Corporate Secretary
PR Newswire - Tue Oct 07, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"
today announced the appointment of Philip A. Theodore, as Senior Vice President, Chief Administrative Officer, General Counsel and Corporate Secretary. Before joining Aeterna Zentaris, Mr. Theodore was Vice President, General Counsel and Corporate Secretary of Zep Inc., a leading consumable chemical packaged goods company. AEZ.TO: 1.33 (+0.05), AEZS: 1.18 (+0.05), ZEP: 14.86 (+0.01)
Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences
PR Newswire - Tue Sep 30, 7:50AM CDT
Investor-Edge has initiated coverage on the following equities: Immunomedics Inc. (NASDAQ: IMMU), Aeterna Zentaris Inc. (NASDAQ: AEZS), OPKO Health Inc. (NYSE: OPK), Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB), and Exact Sciences Corporation (NASDAQ: EXAS). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, September 29, 2014, the NASDAQ Composite ended at 4,505.85, down 0.14%, the Dow Jones Industrial Average finished the day 0.25% lower at 17,071.22, and the S&P 500 closed at 1,977.80, down 0.25%. The losses were broad based as nine out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 744.38, down 0.18%, while the index has advanced 0.92% in the last one month. Register for your complimentary reports on these five stocks at:
IMMU: 3.65 (unch), NAVB: 1.46 (+0.04), OPK: 8.39 (+0.03), AEZS: 1.18 (+0.05), EXAS: 24.22 (+0.36)
Aeterna Zentaris to Present at Upcoming Rodman & Renshaw Annual Global Investment Conference in New York
PR Newswire - Tue Sep 02, 3:15PM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"
today announced that the Company's Chairman and CEO, David Dodd, will be presenting a corporate overview at the Rodman & Renshaw 16th Annual Global Investment Conference on Tuesday, September 9, 2014, at 3:20pm (Eastern), in the Holmes II Salon (4th floor) of the New York Palace Hotel in New York City. AEZ.TO: 1.33 (+0.05), AEZS: 1.18 (+0.05)
Hot Stock: AEterna Zentaris, Shares Gain 5.4% (AEZS)
Comtex SmarTrend(R) - Fri Aug 29, 10:38AM CDT
AEterna Zentaris (NASDAQ:AEZS) is one of today's best performing low-priced stocks, up 5.4% to $1.48 on 3.9x average daily volume. Thus far today, AEterna Zentaris has traded 2.7 million shares, vs. average volume of 682,000 shares per day. The stock has outperformed the Dow (5.4% to the Dow's 0.0%) and outperformed the S&P 500 (5.4% to the S&P's 0.2%) during today's trading.
AEZS: 1.18 (+0.05)
Momentum Indicators for Biotech Stocks -- Exact Sciences, BioCryst Pharma, Spectrum Pharma, Aeterna Zentaris, and CTI BioPharma
PR Newswire - Mon Aug 25, 7:50AM CDT
On Friday, August 22, 2014, the NASDAQ Composite ended at 4,538.55, up 0.14%, the Dow Jones Industrial Average declined 0.22%, to finish the day at 17,001.22, and the S&P 500 closed at 1,988.40, down 0.20%. The losses were broad based as seven out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day flat at 727.35, and the index has advanced 6.75% in the previous three months. Investor-Edge has initiated coverage on the following equities: Exact Sciences Corporation (NASDAQ: EXAS), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), Aeterna Zentaris Inc. (NASDAQ: AEZS), and CTI BioPharma Corporation (NASDAQ: CTIC). Free research on these five companies can be accessed at:
BCRX: 11.37 (-0.23), AEZS: 1.18 (+0.05), SPPI: 7.62 (+0.13), EXAS: 24.22 (+0.36), CTIC: 2.37 (-0.02)
4 Stocks Under $10 to Trade Now
at The Street - Fri Aug 15, 5:00AM CDT
Stocks making big-percentage moves are usually in play because their sector is becoming attractive or they have a major fundamental catalyst.
SALT: 5.19 (+0.23), SNSS: 1.47 (-0.03), AEZS: 1.18 (+0.05), RBCN: 4.43 (+0.22)
Aeterna Zentaris Reports Second Quarter 2014 Financial and Operating Results
PR Newswire - Thu Aug 07, 3:30PM CDT
All amounts are in US dollars
AEZ.TO: 1.33 (+0.05), AEZS: 1.18 (+0.05)
Aeterna Zentaris to Present at Upcoming Canaccord Genuity 34th Annual Global Growth Conference in Boston
CNW Group - Wed Aug 06, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"
today announced that the Company's Chairman, CEO, David Dodd, will be presenting a corporate overview at the Canaccord Genuity 34th Annual Global Growth Conference on Wednesday, August 13, 2014, at 1pm (Eastern), in the Melbourne Room of the Intercontinental Hotel in Boston. AEZ.TO: 1.33 (+0.05), AEZS: 1.18 (+0.05)
Aeterna Zentaris and ASCEND Therapeutics Sign Co-Promotion Agreement for U.S. Market
PR Newswire - Tue Aug 05, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"
today announced a strategic co-promotion services agreement with ASCEND Therapeutics® US, LLC, ("ASCEND" . Under the terms of the agreement, expected to start in the fourth quarter of 2014, Aeterna Zentaris will use its newly established commercial structure to market, in specific U.S. territories, ASCEND's EstroGel® a non-patch transdermal U.S. Food & Drug Administration ("FDA" approved and commercialized estrogen replacement therapy. For its part, ASCEND would market, in specific U.S. territories, MacrilenTM, Aeterna Zentaris' product for use in the evaluation of adult growth-hormone deficiency ("AGHD" , for which a New Drug Application ("NDA" is currently under review by the FDA, with a Prescription Drug User Fee Act ("PDUFA" date of November 5, 2014. In consideration for these co-promotion services, each party will be entitled to receive, from the other party, commissions on net sales of each other's product. AEZ.TO: 1.33 (+0.05), AEZS: 1.18 (+0.05)
Aeterna Zentaris to Announce Second Quarter 2014 Financial and Operating Results on August 7, 2014
CNW Group - Thu Jul 31, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"
will announce its second quarter 2014 financial and operating results after market close on Thursday, August 7, 2014. The Company will host a conference call to discuss these results on Friday, August 8, 2014, at 8:30 a.m. eastern time. AEZ.TO: 1.33 (+0.05), AEZS: 1.18 (+0.05)
Equities to Watch in the Health Care Sector -- ImmunoCellular Therapeutics, Aeterna Zentaris, Lexicon Pharma, BioDelivery Sciences Intl., and Jazz Pharma
PR Newswire - Wed Jul 23, 7:40AM CDT
On Tuesday, July 22, 2014, the NASDAQ Composite ended at 4,456.02, up 0.71%, the Dow Jones Industrial Average finished the day 0.36% higher at 17,113.54, and the S&P 500 closed at 1,983.53, up 0.50%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 713.75, up 0.83%, with the index also advancing 5.99% in the previous three months. Investor-Edge has initiated coverage on the following equities: ImmunoCellular Therapeutics Ltd (NYSE MKT: IMUC), Aeterna Zentaris Inc. (NASDAQ: AEZS), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), BioDelivery Sciences International Inc. (NASDAQ: BDSI), and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Free research on these five companies can be accessed at:
BDSI: 16.35 (-0.39), LXRX: 1.35 (+0.03), JAZZ: 159.35 (+6.96), AEZS: 1.18 (+0.05), IMUC: 0.71 (-0.01)
Traders Get Bullish on Shares of AEterna Zentaris, Shares Up 6.6% (AEZS)
Comtex SmarTrend(R) - Wed Jul 02, 10:09AM CDT
AEterna Zentaris (NASDAQ:AEZS) is one of today's best performing low-priced stocks, up 6.6% to $1.29 on 7.0x average daily volume. AEterna Zentaris has traded 2.7 million shares thus far today, vs. average volume of 386,000 shares per day. The stock has outperformed the Dow (6.6% to the Dow's 0.1%) and outperformed the S&P 500 (6.6% to the S&P's 0.1%) during today's trading.
AEZS: 1.18 (+0.05)
